FDA Risk-Evaluation Guidance Unlikely To Help Generics
Last week, the U.S. Food and Drug Administration issued two draft guidances concerning risk evaluation mitigation strategies, or REMS, which are programs designed to track the use, and deter the potential...To view the full article, register now.
Already a subscriber? Click here to view full article